References
- Amiri A, Fatemi SJ, Fatemi SN. (2007). Removal of thallium by combining desferrioxamine and deferiprone chelators in rats. Biometals 20:159–63.
- Bagchi D, Prasad R, Das DK. (1989). Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem Biophys Res Commun 158:52–7.
- Cappellini MD. (2008). Long term efficacy and safety of deferasirox. Blood Rev 2:35–41.
- Evans RW, Kong X, Hider RC. (2012). Iron mobilization from transferrin by therapeutic iron chelating agents. Biochim Biophys Acta 1820:282–90.
- Fatemi SJ, Tubafard S, Nadi B. (2009). Evaluation of the effect of cadmium on rat organs and investigation of diethyl carbamate as an oral drug in treatment of cadmium toxicity. Med Chem Res 18:179–86.
- Hershko C, Konijn AM, Nick HP, et al. (2001). ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron loaded rat heart cell in culture. Blood 97:1115–22.
- Jones-Lee A, Lee GF. (2005). Role of iron chemistry in controlling the release of pollutants from resuspended sediments. Remediation J 16:33–41.
- Lee DW, Andersen JK, Kaur D. (2006). Iron dysregulation and neurodegeneration: the molecular connection. Mol Interv 6:89–97.
- Linder MC, Hazegh-Azam M. (1996). Copper biochemistry and molecular biology. Am J Clin Nutr 63:797S–811S.
- Ma Y, Zhou T, Kong X, Hider RC. (2012). Chelating agents for the treatment of systemic iron overload. Curr Med Chem 19:2816–27.
- Neufeld EJ. (2006). Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107:3436–41.
- Piga A, Gaglioti C, Fogliacco E, Tricta F. (2003). Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88:489–96.
- Steinhauser S, Heinz U, Bartholoma M, et al. (2004). Complex formation of ICL670 and related ligands with Fe (III) and Fe (II). Eur J Inorg Chem 21:4177–92.
- Tseng CH. (2008). Cardiovascular disease in arsenic-exposed subjects living in the arseniasis-hyperendemic areas in Taiwan. Atherosclerosis 199:12–18.
- Uriu-Adams JY, Keen CL. (2005). Copper, oxidative stress and human health. Mol Aspects Med 26:268–98.
- Valko M, Morris H, Cronin MT. (2005). Metals, toxicity and oxidative stress. Curr Med Chem 12:1161–208.
- Voskaridou E, Christoulas D, Terpos E. (2011). Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting sever iron overload after single-agent chelation therapies. Br J Haematol 154:654–6.
- Westwood M, Anderson LJ, Pennell DJ. (2003). Treatment of cardiac iron overload in thalassemia major. Haematologica 88:481–2.